Pernix Therapeutics Holdings Major Shareholder Sells $61,516 in Stock (PTX)
Pernix Therapeutics Holdings (NYSE:PTX) major shareholder Cooper Collins sold 27,962 shares of the stock on the open market in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $2.20, for a total value of $61,516.40. Following the transaction, the insider now directly owns 6,270,046 shares of the company’s stock, valued at approximately $13,794,101. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Shares of Pernix Therapeutics Holdings (NYSE:PTX) remained flat at $2.22 during during mid-day trading trading on Wednesday. 41,413 shares of the company’s stock traded hands. Pernix Therapeutics Holdings has a 52 week low of $1.68 and a 52 week high of $8.34. The stock’s 50-day moving average is $2.44 and its 200-day moving average is $2.81. The company’s market cap is $82.5 million.
Pernix Therapeutics Holdings (NYSE:PTX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.13) by $0.04. The company had revenue of $18.30 million for the quarter, compared to the consensus estimate of $23.06 million. During the same quarter last year, the company posted ($0.03) earnings per share. Analysts expect that Pernix Therapeutics Holdings will post $-0.62 EPS for the current fiscal year.
PTX has been the subject of a number of recent research reports. Analysts at Cantor Fitzgerald downgraded shares of Pernix Therapeutics Holdings from a “hold” rating to a “sell” rating in a research note to investors on Monday. Separately, analysts at Needham & Company reiterated a “buy” rating on shares of Pernix Therapeutics Holdings in a research note to investors on Wednesday, November 13th. They now have a $5.00 price target on the stock, down previously from $6.00. Finally, analysts at Guggenheim downgraded shares of Pernix Therapeutics Holdings from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, November 13th. They now have a $2.00 price target on the stock, down previously from $10.00. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. Pernix Therapeutics Holdings has a consensus rating of “Hold” and a consensus target price of $3.60.
Pernix Therapeutics Holdings, Inc (NYSE:PTX) is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.